A TACTful reappraisal of chelation therapy in cardiovascular disease

Area of Science:

• Cardiology
• Clinical Trials
• Alternative Medicine

Background:

• Atherosclerotic cardiovascular disease (CVD) is a major cause of death, with many patients seeking alternative therapies.
• Chelation therapy with ethylenediamine tetra acetic acid (EDTA) is an unproven alternative treatment for CVD.
• The Trial to Assess Chelation Therapy (TACT) investigated EDTA chelation for post-myocardial infarction patients.

Purpose of the Study:

• To evaluate the efficacy of chelation therapy with disodium EDTA compared to placebo in patients with established CVD.
• To discuss the results, limitations, and implications of the TACT trial within the broader scientific context.

Main Methods:

• A randomized, placebo-controlled trial (TACT) was conducted.
• Participants included patients who had experienced a myocardial infarction.
• Chelation therapy involved disodium EDTA administration.

Main Results:

• The findings from the TACT trial were deemed not robust.
• The study did not provide strong evidence supporting chelation therapy for CVD.
• A potential exception was noted for high-risk cohorts, such as patients with diabetes mellitus.

Conclusions:

• Chelation therapy with EDTA is unlikely to be widely accepted for CVD treatment without more data.
• Further investigation is required to confirm any potential benefits, particularly in specific patient populations.
• Current evidence does not support the routine use of chelation therapy for cardiovascular disease.